USOR 24189 - Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS)

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Disease Types: Lung - Non-Small Cell Lung

Available at: Arlington Heights, Niles